Showing results (81-90 of 222) with videos related to
Sort By:
Pageof 23
The Journal of Clinical Endocrinology and Metabolism|April 1, 1991
Insulin resistance: an early metabolic defect of Turner's syndromeS Caprio, S Boulware, M Diamond, et al.Molecular Cancer Therapeutics|March 30, 2020
An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate CancerNancy A Dawson, Matthew Zibelman, Timothy Lindsay, et al.International Journal of Radiation Oncology, Biology, Physics|May 10, 2003
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancerLawrence Kleinberg, Jonathan P S Knisely, Richard Heitmiller, et al.Anticancer Research|November 7, 2018
Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate CancerElisabeth I Heath, Lance K Heilbrun, Daryn Smith, et al.Journal of Geriatric Oncology|April 20, 2011
Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experienceSyed F Zafar, Lance K Heilbrun, Prakash Vishnu, et al.Journal of Cancer Therapy|September 24, 2013
Physicians' Use of Patients' Daily Reports of Quality of Life to Evaluate Treatment Response in Phase I Cancer TrialsFelicity W K Harper, Elisabeth I Heath, Marci E J Gleason, et al.Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|December 3, 2003
Chemoprevention for Barrett's esophagus trial. Design and outcome measuresE I Heath, M I Canto, T-T Wu, et al.Molecular Cancer|November 5, 2016
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasisM Katie Conley-LaComb, Louie Semaan, Rajareddy Singareddy, et al.Clinical Genitourinary Cancer|November 29, 2016
Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate CancerRana R McKay, Lillian Werner, Matthew Fiorillo, et al.Patient Education and Counseling|September 9, 2022
Physicians' use of plain language during discussions of prostate cancer clinical trials with patientsLuke Thominet, Lauren M Hamel, Fatmeh Baidoun, et al.Pageof 23